Mr. Marc Edwards reports

KANE BIOTECH TO RELEASE FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS ON MARCH 26, 2024 - CONFERENCE CALL TO FOLLOW

Kane Biotech Inc. will release its fourth quarter and full-year 2023 financial results after market close on Tuesday, March 26, 2024.

Kane Biotech management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period.

Participants must register for the call on-line to receive the dial-in numbers and unique PINs (personal identification numbers) to access the call seamlessly. It is recommended that you join 10 minutes before the event, though you may preregister at any time. A webcast of the call will be available on the company's website in the investor section of the Kane Biotech website.

About Kane Biotech Inc.

Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The company has a portfolio of biotechnologies, intellectual property (67 patents and patents pending, trade secrets, and trademarks) and products developed by the company's own biofilm research expertise and acquired from leading research institutions. StrixNB, DispersinB, Aledex, bluestem, bluestem, silkstem, goldstem, coactiv+, coactiv+, DermaKB, DermaKB Biofilm and revyve are trademarks of Kane Biotech. The company is listed on the TSX Venture Exchange under the symbol KNE and on the OTCQB Venture Market under the symbol KNBIF.

We seek Safe Harbor.